阿尔茨海默病中的德费里:一项随机临床试验
Scott Ayton1,2, David Barton3, Bruce Brew4,5
1The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Australia.
JAMA neurology
|November 4, 2024
概括
这项研究发现,铁合剂deferiprone在阿尔茨海默病 (AD) 患者中加速认知衰退. 用deferiprone降低脑铁似乎是有害的,强调了需要谨慎的治疗方法在AD.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 阿尔茨海默氏症 (AD) 构成一个重大的全球健康挑战,神经退行是一个关键的病理特征.
- 在阿尔茨海默病中,脑铁水平升高与更快的认知衰退相关,这表明铁失调是潜在的治疗目标.
研究的目的:
- 评估Deferiprone的疗效,一个脑透的铁合剂,减缓早期阿尔茨海默病患者的认知衰退.
主要方法:
- 一个为期12个月的,第二阶段,双面罩,安慰剂控制的随机临床试验,涉及81名参与者,他们患有粉胺确认的轻度认知障碍或早期AD.
- 参与者接受了deferiprone (15 mg/kg每天两次) 或安慰剂.
- 主要结果:通过神经心理测试电池 (NTB) 评估认知功能;次要结果:大脑铁负荷 (QSM-MRI),大脑体积和安全的变化.
主要成果:
- 与安慰剂相比,德费里治疗加速了认知衰退,特别是在执行功能方面.
- 定量敏感性映射 (QSM) 证实,在德利组中,海马铁减少.
- 服用德费里时观察到额叶体积损失增加;中性质减退发生的频率更高.
结论:
- 在阿尔茨海默症早期的患者中,德费里治疗减少了海马铁,但加速了认知衰退.
- 这些发现表明,用deferiprone进行铁化可能对AD有害.
- 需要进一步的研究,以了解铁在AD病原和治疗干预中的复杂作用.
相关概念视频
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
01:26Alzheimer's Disease: Overview
449
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
449
01:11Clinical Trials: Overview
2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K